zeneca zd 6169 has been researched along with Tachycardia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calzadilla, SV; Cox, BF; Fryer, RM; Gopalakrishnan, M; Hu, Y; Lin, CT; Marsh, KC; Preusser, LC; Reinhart, GA; Xu, H | 1 |
1 other study(ies) available for zeneca zd 6169 and Tachycardia
| Article | Year |
|---|---|
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine.
Topics: Adenosine Triphosphate; Amides; Animals; Benzophenones; Blood Pressure; Cyclic S-Oxides; Cyclobutanes; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electrocardiography; Heart Rate; Hypotension; Infusions, Intravenous; Ion Channel Gating; Male; Muscle Contraction; Muscle, Smooth; Nifedipine; Nitriles; Pharmaceutical Vehicles; Polyethylene Glycols; Potassium Channels; Quinolones; Tachycardia; Urinary Bladder; Urinary Incontinence; Vascular Resistance | 2004 |